Browse: Departments Dates Agencies
SUBJECT CATEGORY: Manufacturer of Controlled Substances; Notice of Registration
DOCUMENT SUMMARY:
By Notice dated June 26, 2007, and published in the Federal Register on July 5, 2007, (72 FR 36728), Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Lisdexamfetamine (1205), a basic class of controlled substance listed in schedule II.
The company plans to qualify as a bulk manufacturer of the above listed controlled substance.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Boehringer Ingelheim Chemicals, Inc. to manufacture the listed basic
class of controlled substance is consistent with the public interest at
this time. DEA has investigated Boehringer Ingelheim Chemicals, Inc. to
ensure that the company's registration is consistent with the public interest. The
[[Page 64676]]
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic class of controlled substance listed.
Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E722521 Filed 111507; 8:45 am]
BILLING CODE 441009P
SUMMARY: Boehringer Ingelheim Chemicals, Inc.,
DOCUMENT BODY 2:
By Notice dated June 26, 2007, and published in the Federal Register on July 5, 2007, (72 FR 36728), Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Lisdexamfetamine (1205), a basic class of controlled substance listed in schedule II.
The company plans to qualify as a bulk manufacturer of the above listed controlled substance.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Boehringer Ingelheim Chemicals, Inc. to manufacture the listed basic
class of controlled substance is consistent with the public interest at
this time. DEA has investigated Boehringer Ingelheim Chemicals, Inc. to
ensure that the company's registration is consistent with the public interest. The
[[Page 64676]]
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic class of controlled substance listed.
Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E722521 Filed 111507; 8:45 am]
BILLING CODE 441009P
14 CFR Part 39 40 CFR Part 52 14 CFR Part 71 33 CFR Part 165 50 CFR Part 679 47 CFR Part 73 26 CFR Part 1 40 CFR Part 180 33 CFR Part 117 50 CFR Part 17 44 CFR Part 67 50 CFR Part 648 14 CFR Part 97 40 CFR Part 63 33 CFR Part 100 50 CFR Part 622 50 CFR Part 660 26 CFR Part 301 44 CFR Part 65 39 CFR Part 111 40 CFR Part 300 6 CFR Part 5 40 CFR Part 271 47 CFR Part 64 40 CFR Parts 52 and 81 50 CFR Part 665 10 CFR Part 50 44 CFR Part 64 49 CFR Part 571 39 CFR Part 3020